Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER trial: Pembrolizumab omission strategy in elderly stage II triple-negative breast cancer
jRCT1071240119Recruiting
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of pembrolizumab in triple-negative breast cancer (TNBC) (2 arms). Primary endpoints: pathological_complete_response_rate and incidence_of_adverse_events. Started Feb 2025; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT1071240119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071240119.